Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of zoledronic acid
administered intravenously every 3-4 weeks in patients with bone metastases from either
breast cancer or prostate cancer.